CJC-1295

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), also known as growth hormone-releasing factor (GRF). It is primarily used as a research chemical. Its main function is to stimulate the release of growth hormone (GH) from the pituitary gland.

CJC-1295 differs structurally from native GHRH (1-44) in several key aspects. Most notably, it includes four amino acid substitutions that enhance its stability and resistance to enzymatic degradation. It also incorporates a drug affinity complex (DAC), which extends its half-life in the body considerably compared to unmodified GHRH. The DAC is covalently linked to lysine via a maleimide bond. This modification allows it to bind to albumin in the bloodstream, leading to sustained release and prolonged activity.

Because of the DAC, CJC-1295 can cause a long-lasting increase in growth hormone levels and insulin-like growth factor 1 (IGF-1). The duration of action can be several days.

CJC-1295 is available in two forms:

• CJC-1295 without DAC (also referred to as Modified GRF 1-29 or sermorelin): This version has a shorter half-life and requires more frequent administration to achieve similar effects.
• CJC-1295 with DAC: This version, as described above, provides a longer-lasting effect due to the albumin binding.

It's important to note that the use of CJC-1295 is primarily confined to research settings. Its use is not approved by regulatory bodies such as the FDA for human use, and any use for off-label purposes is done at the user's own risk.